Next Article in Journal
Clinical Implementation of Robust Optimization for Craniospinal Irradiation
Next Article in Special Issue
mTOR Pathways in Cancer and Autophagy
Previous Article in Journal
The Role of Chromosomal Instability in Cancer and Therapeutic Responses
Previous Article in Special Issue
Eukaryotic Elongation Factor 2 Kinase (eEF2K) in Cancer
Article Menu
Issue 1 (January) cover image

Export Article

Open AccessReview
Cancers 2018, 10(1), 5; doi:10.3390/cancers10010005

Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression

1
Division of Cancer and Genetics, Cardiff University, Heath Park, Cardiff CF14 4XN, UK
2
School of Biochemistry & Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland
*
Author to whom correspondence should be addressed.
Received: 5 December 2017 / Revised: 27 December 2017 / Accepted: 28 December 2017 / Published: 3 January 2018
(This article belongs to the Special Issue mTOR Pathway in Cancer)
View Full-Text   |   Download PDF [1624 KB, uploaded 3 January 2018]   |  

Abstract

Throughout the years, research into signalling pathways involved in cancer progression has led to many discoveries of which mechanistic target of rapamycin (mTOR) is a key player. mTOR is a master regulator of cell growth control. mTOR is historically known to promote cell growth by enhancing the efficiency of protein translation. Research in the last decade has revealed that mTOR’s role in promoting cell growth is much more multifaceted. While mTOR is necessary for normal human physiology, cancer cells take advantage of mTOR signalling to drive their neoplastic growth and progression. Oncogenic signal transduction through mTOR is a common occurrence in cancer, leading to metabolic transformation, enhanced proliferative drive and increased metastatic potential through neovascularisation. This review focuses on the downstream mTOR-regulated processes that are implicated in the “hallmarks” of cancer with focus on mTOR’s involvement in proliferative signalling, metabolic reprogramming, angiogenesis and metastasis. View Full-Text
Keywords: mTOR; cancer; cell growth; S6K1; 4E-BP1; eIF4E; HIF; STAT3; SGK1 mTOR; cancer; cell growth; S6K1; 4E-BP1; eIF4E; HIF; STAT3; SGK1
Figures

Figure 1

This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).

Scifeed alert for new publications

Never miss any articles matching your research from any publisher
  • Get alerts for new papers matching your research
  • Find out the new papers from selected authors
  • Updated daily for 49'000+ journals and 6000+ publishers
  • Define your Scifeed now

SciFeed Share & Cite This Article

MDPI and ACS Style

Rad, E.; Murray, J.T.; Tee, A.R. Oncogenic Signalling through Mechanistic Target of Rapamycin (mTOR): A Driver of Metabolic Transformation and Cancer Progression. Cancers 2018, 10, 5.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Related Articles

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top